| Atlas Antibodies–Genovis: MS-based analysis of biopharmaceuticals, 202208– supply service LC-MS analytics of recombinant CHO-antibodies to Evitria |
2022-08-08 |
| Atinary Technologies–Bruker: investment, 202608 minority investment €na by Bruker in connection with strategic collaboration |
2026-08-11 |
| Atavistik Bio–SEVERAL: investment, 202108 financing round Series A $60m led by The Columm Group with Lux Capital + Nextech Invest |
2021-08-24 |
| Atavistik Bio–Nextech: investment, 202108 financing round Series A totalling $60m incl co-investor Nextech Invest Ltd |
2021-08-24 |
| Atavistik Bio–Lux Capital: investment, 202108 financing round Series A totalling $60m incl co-investor Lux Capital |
2021-08-24 |
| Atavistik Bio–Column Group: investment, 202108 financing round Series A totalling $60m incl lead investor The Columm Group |
2021-08-24 |
| Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) |
2023-02-15 |
| Aspect Analytics–SEVERAL: investment, 202509 financing round Series A €10m led by PMV + Capricorn Healthtech Fund II |
2025-09-09 |
| As One Corp–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Japan by 1st PhileKorea |
2025-04-09 |
| Applied Technical Services–SGS: investment, 202507–202601 acquisition $1.235b cash-/debt-free with <$100m in shares + rest in cash |
2025-07-02 |
| Andrew Alliance–Waters: investment, 202001 acquisition $80m by existent investor Waters |
2020-01-13 |
| Anaquant–Clean Biologics: investment, 202607 acquisition €na of Anaquant SAS by Clean Cells backed by Archimed (maybe asset deal?) |
2026-07-30 |
| Alphalytik Pharmaservice–Certania: investment, 202409 acquisition of Alphalytik Pharmaservice GmbH by Certania |
2024-09-04 |
| Aldevron–Danaher: investment, 202106– acquisition $9.6b in cash by Danaher ANNOUNCED |
2021-06-17 |
| Alderley Analytical–Synexa Life Sciences: investment, 202410 acquisition of Alderley Analytical Ltd by Synexa |
2024-10-07 |
| Alamar Biosciences–SEVERAL: investment, 202604 IPO $191.25m+$28.688m with 11.25m+1.688m shares common stock incl full over-allotment at Nasdaq |
2026-04-20 |
| Akribion–SEVERAL: investment, 202502 seed financing round €8m led by Carma Fund + RV Invest |
2025-02-04 |
| Akribion–Optimum Strategic Communications: public relations, 202502 service existent by Optimum |
2025-02-04 |
| Akribion–High-Tech Gründerfonds: investment, 202502 seed financing round totalling €8m incl co-investor HTGF |
2025-02-04 |
| Akribion–Bruker: investment, 202502 seed financing round totalling €8m incl co-investor Bruker Invest |
2025-02-04 |
| Akoya Biosciences–SEVERAL: investment, 202306 public offering up to $43.5m+$6.525m with 8.7m+1.305m shares common stock at $5/share |
2023-06-08 |
| Akoya Biosciences–Quanterix: investment, 202501– merger acquisition with former Quanterix shareholders owning 70% ANNOUNCED |
2025-01-10 |
| Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology |
2020-03-02 |
| Agilent–UniteLabs: lab automation technology, 202602 collab existent integration of Agilent instruments into muli-vendor systems of Unite Labs |
2026-02-04 |
| Agilent–Sigsense Technologies: lab management software, 202407 supply existent Sigsense technology available via Agilent CrossLab Connect |
2024-07-29 |
| Agilent–Siemens: laboratory software, 202602– collab expansion to enhance interoperability of OpenLab CDS with Virscidian Analytical Studio s/w |
2026-02-03 |
| Agilent–Scitara: lab informatics, 202209– collab product integration of OpenLab CDS + SLIMS with Scientific Integration Platform SIP + DLX |
2022-09-21 |
| Agilent–Proscia: digital pathology, 202303– collab ww distribution multi-year for Concentriq Dx platform with Agilent digital pathology solutions |
2023-03-08 |
| Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems |
2023-01-18 |
| Agilent–National Univ Singapore: metabolomics, 202410– collab establishment NUS-Agilent CoE in Cell Metabolism incl supply of Agilent instruments |
2024-10-04 |
| Agilent–Mettler-Toledo: lab automation, –202206 collab developm + product integration automated + digitalised sample prep for LC/GC workflow |
2022-06-01 |
| Agilent–HighRes Biosolutions: lab automation technology, 202602 collab existent integration of Agilent instruments into muli-vendor systems of HRBS |
2026-02-04 |
| Agilent–Hamamatsu: digital pathology, 202303– collab distribution of NanoZoomer digital pathology slide scanners by Agilent |
2023-03-10 |
| Agilent–Exact Sciences: investment, 202309– acquisition €na of Resolution Bioscience by Exact Sciences from Agilent |
2023-09-12 |
| Agilent–e-MSion: mass spectrometry technology, 2019– collab co-marketing of ExD cell technology with 6500 Series LC-/Q-TOF |
2023-03-09 |
| Agilent–Bright Giant: mass spectrometry software, 202208– collab developm s/w for AI-based small-molecule identification in mass spec metabolomics |
2022-08-16 |
| Agilent–Bico: lab automation technology, 202602 collab existent integration of Agilent instruments into muli-vendor systems of Biosero |
2026-02-04 |
| Agilent–Akoya Biosciences: IHC diagnostics, 202301– collab developm + marketing solutions integrating Dako Omnis instrument + PhenoImager HT system |
|
| Agilent–ABB: lab automation technology, 202602 collab existent integration of Agilent instruments into muli-vendor systems of ABB Robotics |
2026-02-04 |
| Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe |
2021-04-28 |
| Agena Bioscience–Mesa Labs: investment, 202109– acquisition $300m in cash of Agena by Mesa Laboratories ANNOUNCED |
2021-09-14 |
| AEROSOLS project–Ionicon: PTR-TOF mass spectrometer, 202401–202612 collab Ionicon is project member supplying PTR-TOF mass spec systems + ILOx |
2024-01-01 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp |
2021-01-06 |
| Adaptyv Biosystems–Y Combinator: investment, 202608 financing round Series A totalling $40m incl existing + co-investor Y Combinator |
2026-08-25 |
| Adaptyv Biosystems–SEVERAL: investment, 202608 financing round Series A $40m led by Highland Europe |
2026-08-25 |
| Adaptyv Biosystems–SEVERAL: investment, 2025 seed financing round $8m led by ACE Ventures |
2025-09-18 |
| Adaptyv Biosystems–OTHER: investment, 2025 seed financing round totalling $8m incl angel investors |
2025-09-18 |
| Adaptyv Biosystems–LongGame: investment, 2025 seed financing round totalling $8m incl new + co-investor LongGame |
2025-09-18 |
| Adaptyv Biosystems–Highland Europe: investment, 202608 financing round Series A totalling $40m incl lead investor Highland Europe |
2026-08-25 |
| Adaptyv Biosystems–Founderful: investment, 2025 seed financing round totalling $8m incl existing + co-investor Founderful |
2025-09-18 |
| Adaptyv Biosystems–byFounders: investment, 202608 financing round Series A totalling $40m incl existing + co-investor byFounders |
2026-08-25 |
| Adaptyv Biosystems–byFounders: investment, 2025 seed financing round totalling $8m incl existing + co-investor byFounders |
2025-09-18 |
| Adaptyv Biosystems–ACE Ventures: investment, 202608 financing round Series A totalling $40m incl existing + co-investor ACE Ventures |
2026-08-25 |
| Adaptyv Biosystems–ACE Ventures: investment, 2025 seed financing round totalling $8m incl lead investor ACE Ventures |
2025-09-18 |
| Acquifer Imaging–Bruker: investment, 202301 acquisition $7.6m of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| ACD/Labs–Revvity: investment, 202511– acquisition of ACD/Labs by Revvity definitive agreement announced |
2025-11-10 |
| Accellix–Mérieux: investment, 202601 acquisition remaining 90% of Accellix by bioMérieux for €35m in cash |
2026-01-22 |
| Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash |
2023-08-28 |
| 908 Devices–SEVERAL: investment, 202111 public offering $100.8m net $94.4m with 3.15m shares common stock at $32/share |
2021-11-15 |
| 908 Devices–SEVERAL: investment, 202012 IPO $130m+$19.5m net $136.6m with 6.5m+975k shares common stock at $20/share at Nasdaq Global Market |
2020-12-18 |
| 908 Devices–Securecell: bioprocess control technology, 202106 collab product integration Rebel media analyzer with Lucullus PIMS |
2021-06-22 |
| 908 Devices–Sartorius: bioprocess control technology, 202106 collab product integration Rebel media analyzer with SIMCA data exploratory tool |
2021-06-22 |
| 2bind–Dynamic Biosensors: switchSENSE technology, 202209– collab technology-service with 2bind using HeliX biosensor system as certified beta customer |
2022-09-01 |
| 1st PhileKorea–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in South Korea by 1st PhileKorea |
2025-04-09 |
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spec-capital-portal-logo.svg){kind=logo}
1 2 3 4 5 6
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
